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Abstract 
Background: We have previously shown that endogenously active purinergic P2X7 receptors (P2X7Rs) in satellite 
glial cells of dorsal root ganglia (DRGs) stimulate ATP release. The ATP activates P2Y1Rs located in the enwrapped neu‑
ronal somata, resulting in down‑regulation of P2X3Rs. This P2X7R‑P2Y1‑P2X3R inhibitory control significantly reduces 
P2X3R‑mediated nociceptive responses. The underlying mechanism by which the activation of P2Y1Rs inhibits the 
expression of P2X3Rs remains unexplored.
Results: Examining the effect of the activation of p38 mitogen‑activated protein kinase on the expression of P2X3Rs 
in DRGs, we found that the p38 activator, anisomycin (Anis), reduced the expression of P2X3Rs. Blocking the activity 
of SGCs by the glial Krebs cycle inhibitor, fluorocitrate, did not change the effect of Anis. These results suggest that 
neuronal p38 plays a major role in the inhibition of P2X3R expression. Western blotting analyses showed that inhibit‑
ing P2Y1Rs by MRS2179 (MRS) or blocking P2X7Rs by either oxATP or A740003 reduced pp38 and increased P2X3R 
expression in DRGs. These results are further supported by the immunohistochemical study showing that P2X7R and 
P2Y1R antagonists reduce the percentage of pp38‑positive neurons. These observations suggest that activation of 
P2X7Rs and P2Y1Rs promotes p38 activity to exert inhibitory control on P2X3R expression. Since activation of p38 by 
Anis in the presence of either A740003 or MRS could overcome the block of P2X7R‑P2Y1R inhibitory control, p38 in 
DRG neurons is downstream of P2Y1Rs. In addition, inhibition of p38 by SB202190 was found to prevent the P2X7R 
and P2Y1R block of P2X3R expression and increase P2X3R‑mediated nociceptive flinch behaviors.
Conclusions: p38 in DRG neurons downstream of P2Y1R is necessary and sufficient for the P2X7R‑P2Y1R inhibitory 
control of P2X3R expression.
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Background
DRG neurons are primary sensory neurons which convey 
somatic and visceral sensory information, including pain 
sensation, from peripheral tissues to the spinal cord. The 
cell bodies (somata) of DRG neurons are tightly packed 
in the ganglion [1]. The unique morphological features of 
DRG neurons are that the somata of DRG neurons lack 
dendrites and do not form synaptic connections with 
each other [2]. Instead, each soma is tightly wrapped 
by a layer of SGCs. The soma-SGC unit is enclosed by a 
connective tissue sheath to form a structural unit [1, 3]. 
This structural arrangement between neuronal soma and 
SGCs suggests that soma-SGC-soma communication 
is essential for determining the somatic activity of DRG 
neurons.
The robust release of ATP from the somata of DRG neu-
rons [4] and the abundant expression of purinergic recep-
tors in neurons and SGC cells in DRGs and trigeminal 
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ganglia suggest that purinergic signaling is a major means 
used by neuronal somata and SGCs in sensory ganglia to 
communicate with each other [5–12]. Among the seven 
ionotropic purginergic P2XR subtypes (P2X1-P2X7R), 
P2X3R is the most abundantly expressed subtype in DRG 
neurons and plays a key role in the transmission of noci-
ceptive information [10, 13–17]. In contrast, P2X7R is 
the most abundantly expressed P2XR subtype in SGCs of 
DRGs [4, 18–20]. Activation of P2X7Rs has been impli-
cated in apoptosis, maturation and release of cytokines, 
regulation of receptor trafficking and production and 
maintenance of pain in the brain and spinal cord [21–24]. 
We and others have shown that the P2X7R expression 
is not detectable in neurons and P2X3Rs are not found 
in SGCs of DRGs [4, 18–20]. This exclusive expression 
of P2X3R in neurons and P2X7R in SGCs facilitates our 
determination of the interaction between glial P2X7Rs 
and neural P2X3Rs. We showed previously that P2X7Rs 
in SGCs are endogenously active and mediate a signifi-
cant portion of the basal ATP release in the DRG [10, 20]. 
The released ATP activates the metabotropic P2Y1Rs in 
the somata of DRG neurons and reduces the expression 
of P2X3Rs. This P2X7R-P2Y1R-P2X3R control exists in 
both adult and immature rats [20, 25]. The mechanism by 
which the activation of P2Y1Rs leads to the reduction of 
P2X3R expression has yet to be elucidated.
p38, together with ERK and JNK, is a major member of 
MAPKs [26]. In response to signals or stress, p38 MAPK, 
a serine-threonine kinase, is phosphorylated and acti-
vated to regulate cytosolic and nuclear targets [27, 28]. 
Inflammation and nerve injury were found to upregu-
late phosphorylated p38 (pp38) in both neuronal somata 
and SGCs of primary sensory ganglia [29] and in spinal 
microglia [28, 30, 31]. Activation of purinergic recep-
tors, P2X4Rs [32], P2X7Rs [33] and P2Y12 [34] in micro-
glia of the spinal cord and P2Y1R in DRG neurons and 
peripheral terminals [35] have been shown to upregulate 
pp38, which led to thermal or mechanical hypersensitiv-
ity. Here we show that in contrast to the pain-producing 
effects of p38, activation of neuronal p38 also plays a crit-
ical role in P2Y1R-mediated inhibitory control of P2X3R 
expression in DRG neurons.
Results
Activation of p38 reduces the expression of P2X3Rs in DRG 
neurons
We showed, in a previous study, that P2X3R expression 
in DRG neurons is regulated by P2X7R-P2Y1R inhibi-
tory control [20]. To determine if p38 is involved in 
the P2X7R-P2Y1R-P2X3R pathway, we examined the 
effect of p38 activation on P2X3R expression. DRGs 
were acutely removed from rats and incubated with the 
p38 activator, anisomycin (Anis) (10  nM), for 1  h. The 
expression of P2X3Rs in DRGs, examined with Western 
analyses, was significantly reduced (Fig. 1a).
Since p38 is expressed in both neurons and SGCs in 
DRGs [29], it is of interest to determine if neuronal- and/
or glial p38 participate in the regulation of P2X3Rs. The 
effect of Anis on P2X3R expression in the presence of the 
glia Krebs cycle inhibitor, fluorocitrate (FC), which dis-
rupts the function of SGCs was studied. We found that 
Anis reduced P2X3R expression to a similar extent with 
and without FC (Fig. 1a). This observation suggests that 
the activation of “neuronal” p38 is sufficient to inhibit 
P2X3R expression.
Fig. 1 Activation of neuronal p38 reduces the expression of P2X3R. 
a Pre‑treatment of DRGs with Anis (10 nM, 1 h) significantly reduced 
the P2X3R expression in DRGs [Anis/Con, 0.72 ± 0.04, n(Con) = 5, 
n(Anis) = 8]. Treating DRGs with both FC (100 µM) and Anis did not 
alter the inhibitory action of Anis on P2X3R expression [(Anis + FC)/
Con = 0.74 ± 0.07 (mean ± SEM), n(Con) = 5, n(Anis + FC) = 6]. b 
Pre‑treatment of DRGs with Anis (10 nM, 1 h) did not alter the P2X7R 
expression [Anis/Con, 1.15 ± 0.05, n(Con) = 4, n(Anis) = 3)]. c Treat‑
ing DRGs with the JNK inhibitor, SP600125 (SP) (2 µM) did not change 
the P2X3R expression [SP/Con = 0.93 ± 0.13 n(Con) = 4, n(SP) = 3]. 
*P < 0.05 compared with Con; NS not significant, P > 0.05
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Anis is known to also inhibit protein synthesis [36]. To 
eliminate this possibility, we examined the effect of Anis 
on the expression of another puringeric receptor, i.e., 
the P2X7R. In contrast to P2X3Rs, Anis had no effect 
on the expression of P2X7Rs (Fig.  1b). Thus, Anis, at 
10  nM (=0.265  ng/ml), does not affect the protein syn-
thesis of purinergic receptors. In addition, Anis can also 
activate JNKs to affect cell activity [37]. To determine if 
Anis block of P2X3R expression can be attributable to 
JNKs activation, the effects of Anis on P2X3R expression 
with and without pretreatment with the JNKs inhibi-
tor, SP600125 (2  µM), were compared. SP600125 had 
no effect on P2X3R expression (Fig.  1c). These results 
strongly suggest that Anis reduces P2X3R expression 
through its activation of p38.
To further confirm that Anis treatment indeed activates 
pp38 in DRGs, we examined the pp38 expression using 
Western blotting analyses. Anis increased pp38 expres-
sion in a dose dependent manner (Fig. 2a). We then used 
immunohistochemical (IHC) experiments to determine 
the distribution of pp38 in DRG neurons. pp38 was found 
in ~20 % of DRG neurons in control rats (Fig. 2b). After 
Anis (10  nM) treatment, a majority of neurons (~74  %) 
expressed pp38.
Colocalization of pp38 and P2X3Rs in DRG neurons 
was also determined. We labeled neurons with both pp38 
and P2X3R antibodies and found that ~20 % P2X3R posi-
tive neurons expressed pp38; ~33  % of pp38-containing 
cells were P2X3R-positive (Fig. 2c).
p38 is involved in the P2X7R‑P2Y1R inhibitory control 
of P2X3Rs
In our previous studies, we showed that endogenously 
activated P2X7Rs in SGCs evoke ATP release from sat-
ellite cells to activate P2Y1Rs in neurons and P2X7R-
P2Y1R exerts inhibitory control of P2X3R expression 
in DRGs [20]. To determine the role of p38 in the 
P2X7R → P2Y1R → P2X3R pathway, the pp38 expression 
was determined in the presence of the P2X7R antagonist, 
oxATP, or the P2Y1R antagonist, MRS2179 (MRS). Both 
oxATP and MRS inhibited the level of pp38 (Fig.  3a), 
suggesting that p38 activity is regulated by P2X7Rs and 
P2Y1Rs. In another set of experiments, we used a specific 
P2X7R antagonist A740003 to inhibit P2X7R and found 
that pp38 expression was similarly inhibited (Fig. 3b), thus 
confirming that P2X7R promotes the expression of pp38. 
We then used the P2Y1 agonist, 2mesADP [38], to further 
examine the participation of P2Y1Rs in the control of p38 
expression.  2mesADP was found to increase the expres-
sion pp38 (Fig.  3c, left). Because 2mesADP is known to 
activate P2Y1, P2Y12 and P2Y13 receptors [39], we deter-
mined if the observed action of 2mesADP is mediated by 
P2Y1Rs. When DRGs were treated with both 2mesADP 
and the P2Y1R antagonist MRS, 2mesADP no longer 
altered pp38 expression (Fig.  3c). Thus, the observed 
2mesADP effect on pp38 is mediated by P2Y1Rs. These 
experiments confirmed the involvement of P2X7 and 
P2Y1R in promoting p38 activity in DRGs.
In addition, IHC analyses were used to determine the 
effect of P2X7R antagonist, A74003 or the effect of the 
P2Y1R antagonist, MRS, on the percentage of pp38-posi-
tive cells expressed in DRG neurons. Both antagonists sig-
nificantly decreased the number of pp38 positive neurons 
(Fig. 4), further confirming the involvement of the P2X7R 
and P2Y1R in promoting the p38 activity in DRG neurons.
Fig. 2 Activation of pp38 by Anis in DRGs. a Pre‑treatment of DRGs 
with Anis increased the expression of pp38 in a dose‑dependent 
manner [Anis (10 nM)/Con, 1.64 ± 0.13, n = 4; Anis (100 nM)/Con, 
3.06 ± 0.20, n = 4). b Intrathecal application of Anis (10 nM) signifi‑
cantly increased the percentage of pp38 positive neurons in DRGs. 
Con, Anis: labeled DRG cells with the pp38 antibody in control and 
Anis treated DRG slices. Percentages of pp38 positive neurons were 
20.4 ± 3.1 % (Control) and 74.0 ± 11.4 % (Anis). c Double labeled DRG 
neurons with pp38 and P2X3R antibodies. About 20 % P2X3R positive 
cells expressed pp38. Arrows cells labeled with both P2X3R and pp38. 
Calibration bar 50 µm, *P < 0.05 compared with Con
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p38 is downstream of P2X7R‑P2Y1R inhibitory control
We then determined if p38 can control the P2X3R expres-
sion in the absence of P2X7R or P2Y1R activation. Blocking 
P2X7R activation by the P2X7R antagonist, A740003 was 
found to enhance P2X3R expression in DRGs. Studying the 
effect of the p38 activator, Anis, in the presence of A740003, 
we found that Anis could overcome A740003-induced 
enhancement of P2X3R expression (Fig. 5, left). Similarly, 
using the P2Y1R antagonist, MRS, to block P2Y1R activa-
tion, P2X3R expression was also increased (Fig.  5, right). 
Again, Anis blocked the MRS-induced increase in the 
expression of P2X3R. These observations suggest that p38 
Fig. 3 P2X7R and P2Y1R regulate pp38 expression. a Inhibition of 
P2X7R or P2Y1R activity reduces pp38 expression. Treating DRGs with 
the P2X7R antagonist, oxATP (100 µM), or with the P2Y1R antagonist, 
MRS2179 (60 µM) for 3 h greatly diminished the expression of pp38 
(oxATP/Con, 0.16 ± 0.10; MRS/Con, 0.39 ± 0.10, n = 3, *P < 0.05). b 
Incubation of DRGs with the specific P2X7R antagonist A740003 (A74) 
also decreased the pp38 expression [(A740003/Con, 0.42 ± 0.08, n 
(Con) = 9, n(740003) = 7, *P < 0.05]. c (Left) Treating DRGs with the 
P2YR agonist, 2mesADP (100 µM), increased the pp38 expression 
(2mesADP/Con = 1.53 ± 0.11,*P < 0.05). (right) Incubation of the 
P2Y1R antagonist, MRS, with 2mesADP blocked the enhancing effect 
of 2mesADP on pp38 expression (Con/2mesADP + MRS, 1.05 ± 0.08, 
n = 3, NS, P > 0.05)
Fig. 4 IHC evidence of the involvement of P2X7R and P2Y1R in the 
regulation of pp38 expression. Intrathecal applications of the P2X7R 
antagonist, A740003 (A74) (250 nM) or the P2Y1R antagonist MRS 
(60 µM) at 10 µl, twice a day for 3 days, significantly inhibited the per‑
centage of pp38 positive neurons in DRGs (Control: 20.40 ± 3.10 %, 
A740003: 8.00 ± 3.33 % and MRS: 1.93 ± 1.93 %) calibration bar: 
50 µm, n = 3, *P < 0.05 compared with control
Fig. 5 p38 is downstream of P2X7R‑P2Y1R control of P2X3R 
expression. a Blocking P2X7R activation with the P2X7R antagonist, 
A740003 (A74) (250 nM), caused an increase in the P2X3R expression 
in DRGs [A74/Con, 2.17 ± 0.13, n(Con) = 14, n (A74) = 9]. Activat‑
ing p38 with Anis (10 nM) overrode the enhancing effect of A74 on 
P2X3R expression [(Anis + A74)/Con = 0.98 ± 0.11, n(Con) = 14, 
n (Anis + A74003) = 9]. b Blocking P2Y1R activation with MRS 
increased P2X3R expression [MRS/Con, 2.17 ± 0.19, n(Con) = 14, 
n(MRS) = 9]. In the presence of Anis, MRS no longer augmented the 
P2X3R expression [(Anis + MRS)/Con = 0.93 ± 0.14, n(Con) = 14, 
n(Anis + MRS) = 8]. NS: P > 0.05; *P < 0.05 compared with [A74 
(−) + Anis (−)] (a) or with [MRS (−) + Anis (−)] (b); #P < 0.05 com‑
pared with [A74 (+) + Anis (+)] (a) or with [MRS (+) + Anis (+)] (b)
Page 5 of 10Chen et al. Mol Pain  (2015) 11:68 
is located downstream of the P2X7R-P2Y1R pathway to 
control the P2X3R expression in DRG neurons.
Activation of p38 in neurons is necessary for P2X7R‑P2Y1R 
inhibitory control of P2X3R expression
We next examined if P2X7R-P2Y1R inhibitory control of 
P2X3Rs can exist in the absence of p38. Freshly removed 
DRGs were incubated with the p38 inhibitor, SB, for 3 h 
and P2X3R expression was then probed. We found that 
SB enhanced the expression of P2X3Rs (Fig. 6a). In addi-
tion, treating DRGs with SB significantly increased the 
number of P2X3R positive neurons in DRG neurons 
(Fig.  6b). These results suggest that without p38 activa-
tion, P2X7-P2Y1 could not exert its inhibitory control on 
the P2X3R expression.
The functional consequence of p38 activation in the 
P2X7R-P2X3R inhibitory control of P2X3R expression 
was also determined. Following the synthesis of P2X3Rs 
in the somata of DRGs, the receptors are transported to 
peripheral and central nerve terminals for pain signaling. 
An intradermal hindpaw injection of the P2XR agonist, 
αβ-meATP, elicited the rat to lift its injected paw repeti-
tively (flinching) (Fig. 6c). This nocifensive behavior is a 
result of the activation of P2X3Rs [17, 20, 40]. Intrathecal 
injections of the p38 inhibitor, SB, induced exaggerated 
nociceptive flinching responses (Fig. 6c). Thus, the inhibi-
tion of p38 eliminates P2X7-P2Y1 inhibitory control sig-
nificantly and increases the P2X3R-mediated nociceptive 
responses at the DRG level. Both the Western and behav-
ioral analyses suggest that activation of p38 is necessary 
for the inhibitory control of P2X3Rs expression through 
the P2X7R-P2Y1R pathway. From these observations, we 
conclude that an activation of P2X7R-P2Y1R would lead 
to the activation of p38 and down-regulation of P2X3Rs, 
resulting in less P2X3Rs transported to the central and 
peripheral nerve terminals (Fig. 7).
Discussion
Our studies show that activation of p38 in DRG neurons 
plays a critical role in the P2X7-P2Y1 inhibitory con-
trol of P2X3R expression in neurons (Figs.  1, 3). Since 
the disruption of SGC functions by the glia Krebs cycle 
inhibitor, FC, does not affect the inhibitory action of p38 
on P2X3R expression (Fig. 1a), the observation suggests 
that the p38 in SGCs is not involved in the P2X7-P2Y1 
control and the activation of neuronal p38 is sufficient to 
control the P2X3R expression in DRG neurons.
The p38 activator, Anis, is known to be a protein syn-
thesis inhibitor [36]. It has been shown that Anis, at the 
dose (10 nM) used in our study, rarely affects the incor-
poration of [3H]lysine into protein in DRGs [36]. This 
together with our finding that Anis inhibits the P2X3R 
but not P2X7R expression (Fig.  1b) strongly supports 
our assertion that the Anis effect on P2X3R expression is 
through its activation of p38 activity, rather than an effect 
on protein synthesis. Pretreatment the JNK inhibitor, 
SP600125, did not alter the Anis effect on P2X3R con-
firming that JNKs are not involved in the action of Anis 
on P2X3R expression (Fig. 1c).
Fig. 6 Activation of p38 in neurons is necessary for the P2X7R‑P2Y1R 
inhibitory control of P2X3R expression. a p38 activation is required 
for P2X7‑P2Y1R inhibitory control of P2X3Rs. P2X3R expression was 
enhanced when p38 activity was inhibited by SB (100 µM, 3 h) (SB/
Con, 1.60 ± 0.14, n(Con) = 8, n(SB) = 7, *P < 0.05) b Intrathecal appli‑
cation of SB (100 µM) increased the  % of P2X3R positive neurons 
(Control: 39.5 ± 0.8 %, SB: 52.8 ± 4.3 %. n = 3) *P < 0.05, bar = 50 µm. 
c In SB treated rats, α,β‑meATP induces exaggerated flinch behav‑
ioral responses in the absence of activation of p38 (n = 4) (ANOVA, 
*P < 0.05)
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Since p38 activation can overcome the blocking action 
of P2X7Rs or P2Y1Rs on P2X3R expression (Fig.  5), 
this places p38 downstream of the P2X7-P2Y1 pathway 
(Fig.  7). In the presence of the p38 blocker, SB, P2X7R-
P2Y1R can no longer exert an inhibitory control of 
P2X3R expression (Fig.  6), leading to the conclusion 
that p38 activation is necessary for the P2X7-P2Y1R 
inhibitory control of P2X3R expression to take place. 
Activation of p38 would result in a reduction in P2X3R 
expression in neuronal somata and thus less P2X3Rs 
transported to the central and peripheral nerve terminals 
(Fig. 7). This would reduce pain perception in the periph-
ery or synaptic transmission in the spinal cord.
Under control conditions, pp38 was found in ~20 % of 
P2X3R-positive DRG neurons (Fig.  2) and P2X3R was 
present in ~40 % of the neurons (Fig. 6). Thus, it appears 
that only ~8  % of all DRG neurons or ~8/40  =  ~20  % 
of P2X3R-containing neurons express pp38 and exert 
P2X7-P2Y1R inhibitory control of P2X3R expression. 
This is unlikely to be accurate because pp38 was found 
to be endogenously active under control conditions 
(Fig. 6b). As a result of pp38 inhibition of P2X3R expres-
sion in those cells, the number of pp38 and P2X3R dou-
ble-labeled cells would be underestimated. Treatment 
of DRG with the p38 inhibitor, SB, resulted in a ~13  % 
increase in P2X3R neurons expressing p38 (Fig.  6b), 
suggesting that ~(8 +  13) =  ~21  % of total neurons or 
~21/(40  +  13)  =  ~40  % of P2X3R-containing neurons 
may express both P2X3R and pp38. This rough estimate 
illustrates the likelihood that a substantial percentage of 
P2X3R-containing cells exert pp38-dependent P2X7-
P2Y1 inhibitory control of the P2X3R expression.
We observed an increase in P2X3R expression in com-
plete Freund’s Adjuvant (CFA)-treated inflamed rats, 
even though the P2X7R expression is upregulated [15, 
20]. Others showed that p38 is activated in DRG neu-
rons after inflammation [41]. Thus, the enhancements 
in endogenous P2X7Rs and p38 are insufficient to block 
all of the increase in P2X3R expression induced by CFA. 
Additional activation of P2X7R was found to be required 
to block the CFA-induced P2X3R upregulation [10, 20].
In the periphery, injury-induced p38 activation mostly 
occurs in neurons [35, 42, 43]. Following tissue or nerve 
injury, mast cells, macrophages, neutrophils, keratino-
cytes and Schwann cells are recruited and/or activated 
at injured sites [44–46]. Inflammatory mediators, e.g., 
TNFα, nerve growth factor (NGF) and ATP are upregu-
lated and released from those non-neuronal cells. They 
act directly on their receptors at sensory neurons, nerve 
fibers and their terminals [47–50] or indirectly through 
the release of prostanoids, e.g. PGE2 [51]. Initiation of 
mechanical allodynia induced by spinal nerve ligation has 
been attributed to TNFα-induced transient increase in 
pp38 in DRG neurons [42]. Exogenously-applied TNFα 
was found to activate p38 in cultured DRG neurons and 
increase TTX-resistant Na+ channel activity [43]. NGF 
was shown to activate p38 to potentiate TRPV1 responses 
after inflammation [41]. It has been shown that activa-
tion of P2Y1R in DRGs induces thermal sensitization or 
hyperalgesia [35, 52]. Kwon et al. [35] further found that 
activation of P2Y1Rs in peripheral nerve terminals by 
ATP released from damaged tissues after carrageenan-
induced inflammation enhances pp38 expression in DRG 
neurons and results in TRPV1 upregulation.
There are fewer examples that p38-mediated changes 
in receptor or channel activity result in the reduction 
of hyperalgesia or chronic pain. Bhattacharjee’s group 
found that activation of p38 increased the activities of 
Na+ activated K+ channels thus reducing the activity of 
DRG neurons [53]. In our study, we showed that the acti-
vation of P2Y1Rs in neurons, induced by ATP released 
from activated P2X7R in SGCs, increases neuronal pp38 
production (Fig. 3). Instead of causing an increase in the 
activity in DRG somata, this results in down-regulation 
of P2X3R expression and thus a reduction of nociceptor 
activity (Figs. 6, 7) [20].
Major differences exist between our results and those of 
Kwon et al. [35]. In addition to the opposite consequence 
between the excitatory P2Y1  →  pp38  →  TRPV1 cas-
cade and inhibitory P2Y1 → pp38 → P2X3 cascade, the 
characteristics of the two responses are different. In the 
P2Y1 → pp38 → TRPV1 cascade, application of a P2Y1 
agonist is required to stimulate the expression of TRPV1. 
Thermal hyperalgesia, but not mechanical allodynia, is 
affected by a P2Y1 antagonist [35]. In our previous study, 
Fig. 7 A schematic shows the involvement of p38 in P2X7R‑P2Y1R‑
P2X3R inhibitory control. Activation of P2X7R‑P2Y1R leads to the 
activation of p38 in DRG neurons. p38 down‑regulates P2X3Rs and 
results in reduction of nociception
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applications of a P2Y1 agonist can alter mechanical allo-
dynia induced by CFA (Figure S6 in [20]). It is of inter-
est to determine the downstream events controlled by 
pp38 activation to produce pain-causing upregulation of 
TRPV1 versus analgesic down-regulation of P2X3Rs.
Since p38 activation was found mostly to enhance 
hyperalgesia, many proposed to use p38 inhibitors to 
treat chronic pain conditions [54]. There are at least two 
possible drawbacks to such an approach. One is that 
p38 is involved in many cell functions in addition to 
the induction of chronic pain [46, 54, 55]. Blocking p38 
may also disrupt some essential cell functions and pro-
duce unexpected side effects. The second drawback is 
that such an approach not only blocks the pain-inducing 
effects, but also inhibits pain-reducing actions of p38 as 
we observed here. As we have shown before [4, 10, 20], 
P2X7R activation produces both excitatory and inhibi-
tory action on P2X3R responses in DRGs, thus providing 
complex and interesting modulations of P2X3R activity. 
A better strategy is to aim at downstream targets of p38 




Male Sprague–Dawley rats (250–350  g) were anesthe-
tized with pentobarbital (50  mg/kg, i.p.) or with halo-
thane (3  % for induction and 2  % for maintenance). L4 
and L5 DRGs were used for experiments. All experimen-
tal procedures were approved by the Institutional Animal 
Care and Use Committee at University of Texas Medical 
Branch and were in accordance with the guidelines of 
the National Institutes of Health and of the International 
Association for the Study of Pain (IASP).
Western blots
L4 and L5 DRGs were removed from normal rats and 
recovered in an oxygenated external solution (in mM) 
(130 NaCl, 5 KCl, 2 KH2PO4, 2.5 CaCl2, 1 MgCl2, 10 glu-
cose, and 10 HEPES, pH7.4, osmolarity, 295–300 mosM) 
at room temperature for 30 min. DRGs were then treated 
with various drugs dissolved in the same solution for 
1–3 h. DRGs were lysed in RIPA buffer (Thermal Scien-
tific) containing protease inhibitor cocktail (Roche). For 
pp38 experiments, phosphatase Inhibitor III (Sigma) 
and phosphatase Inhibitor II (Sigma) were added into 
the RIPA buffer [56]. The cell lysates were centrifuged 
at 10,000×g for 10  min at 4  °C. Equal volumes of total 
protein sample from each group determined by BCA 
(Pierce) were loaded onto a SDS-PAGE, transferred to a 
PVDF membrane, incubated with a blocking buffer (1× 
TBS with 5 % w/v fat free dry milk) for 2 h, and then with 
rabbit anti-P2X3R (1:1000; Alomone) for 2  h at room 
temperature, or with mouse anti-pp38(1:1000; Cell Sign-
aling) for 24  h at 4  °C. The PVDF membrane was then 
washed 5 times with TBST (1× TBS and 0.1 % Tween 20), 
incubated with Clean-Blot IP Detection Reagent (HRP) 
(1:1000; Thermo Scientific) for 1 h at room temperature 
and washed 5 times with TBST. For pp38 experiments, 
we used anti-mouse peroxidase-conjugated secondary 
antibody (1:1000, Chemicon). The immunoreactive pro-
teins were detected by an enhanced chemiluminescence 
kit (Amersham Biosciences) and visualized by exposing 
the PVDF membrane onto an X-ray film. Loading con-
trols were determined by re-probing the membrane with 
mouse anti-Actin (1:30,000, Chemicon) for 2  h or with 
rabbit anti-p38 (1:200; Santa Cruz) overnight at 4 °C for 
the pp38 experiment. After washing, the membrane was 
incubated with Blotting Grade Affinity Purified Goat 
Anti-Mouse IgG (H + L)-HRP Conjugate (1:15,000; Bio-
Rad) for 1  h or with anti-rabbit peroxidase-conjugated 
secondary antibody (1:1000; Santa Cruz) for 1 h at room 
temperature. The intensity of protein bands was deter-
mined using the ImageJ software.
Immunohistochemical procedure
To study the effect of a drug on the distribution of pp38 
and/or P2X3Rs in DRG neurons, 10  µl of the drug at a 
proper concentration was applied intrathecally twice a 
day for 3 days. Rats were then deeply anesthetized with 
pentobarbital (80  mg/kg, i.p.) and transcardially per-
fused with normal saline (~50 ml) followed by a fixative 
(4  % paraformaldehyde plus 0.2  % picric acid in 0.1  M 
phosphate buffer, ~300 ml). L4 and L5 DRGs were then 
removed, put in a 30  % sucrose solution and stored 
at 4  °C overnight. Tissue was then embedded in OCT 
compound with liquid nitrogen and stored at −70  °C. 
Transverse sections of DRGs (10 µm thick) were cut on a 
cryostat and thaw-mounted onto glass slides. After dry-
ing, tissue sections were washed with PBS three times 
and incubated in PBS containing 10 % normal goat serum 
and 0.3 % Triton-100 for 1 h to block non-specific bind-
ing. The sections were then incubated with primary 
guinea pig anti-P2X3 receptor polyclonal antibody (Mil-
lipore, 1:5000) for 48  h or rabbit anti-pp38 monoclonal 
antibody (Cell Signaling, 1:500) for 36  h. After washing 
with PBS, the sections were incubated with secondary 
Alexa Fluor 594 conjugated goat anti-guinea pig IgG (Inv-
itrogen, 1:200) or secondary Alexa Fluor 488 conjugated 
goat anti-rabbit IgG (Invitrogen, 1:200) for 1 h. Primary 
and secondary antibodies were diluted in PBS containing 
1  % normal goat serum and 0.3  % Triton-100. To dou-
ble stain the tissue with P2X3R and pp38, sections were 
stained first with P2X3 receptor antibody and stained 
subsequently with pp38 antibody using the procedures 
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described before. All staining procedures were conducted 
at room temperature.
Drug application
To block the activity of P2X7Rs, either the P2X7R 
antagonist oxATP (100  µM, Sigma) [57] or a highly 
selective P2X7R antagonist A740003 (250  nM, Sigma) 
was used. At 250 nM, A740003 inhibits >90 % of P2X7 
receptor-mediated Ca2+ influx [58]. To activate P2Y1Rs, 
the agonist 2mesADP (100  µM, Sigma) was used. At 
100 µM, 2mesADP was found to excite P2Y1 receptors 
in inhibitory neurons in the hippocampal slice [38]. 
To inhibit P2Y1R activity, the potent selective P2Y1R 
antagonist, MRS (60  µM, Tocris) was incubated with 
DRGs. In neocortical subventricular zone slices, MRS, 
at 50  µM, effectively blocks P2Y1R-mediated Ca2+ 
responses in intermediate neuronal progenitors [59]. To 
study the role of p38 in P2Y1R–P2X3R control, either 
the p38 inhibitor, SB (100 µM, Tocris) or the p38 activa-
tor, Anis (10 nM, Sigma) was used [60, 61]. The function 
of SGCs was disrupted by incubating DRGs in the glia 
Krebs cycle inhibitor, FC, (100 µM, Sigma) [62]. Unless 
stated otherwise, the incubation time for chemicals was 
1 h.
Behavioral experiments
All behavioral studies were performed under blind condi-
tions. To inhibit the activity of p38, SB (100  µM, 10  µl) 
was applied intrathecally twice a day for 3  days. The 
behavioral experiment was started on the 4th day. Flinch-
ing of the rat left hindpaw in response to an intradermal 
paw injection of the P2X receptor agonist, α,β-meATP 
(50  nmole in 50  µl), was used to assess nociception 
elicited by activation of P2X3Rs [17, 63]. The nocifen-
sive behavior was analyzed according to a previously 
described method [17, 40]. In response to α,β-meATP 
injection, rats not only lifted the injected paw more 
frequently, but also kept the paw in the air for a longer 
period. We therefore used paw withdrawal (PW) dura-
tion, i.e., the accumulative duration that the hindpaw was 
lifted in the air in a 1  min time bin, to assess flinching 
behaviors. Since PW duration depends on both paw lift 
frequency and duration, it gives a more accurate measure 
of nociception than flinching frequency, i.e., the num-
ber of paw lifts per min—a parameter commonly used to 
assess flinching behaviors.
Data analyses
Data were expressed as mean  ±  SE. When the signifi-
cance of changes between two groups was assessed, 
Student’s t test was used for data that were normally 
distributed. The Mann–Whitney Rank Sum Test was 
used when the normality test failed. When means from 
more than two groups were compared, one-way analy-
sis of variance (ANOVA) followed by the Holm-Sidak 
post hoc test was used with normally distributed data 
sets. Kruskal–Wallis One Way Analysis of Variance on 
Ranks followed by Dunn’s Method was used when data 
were not normally distributed. A P < 0.05 was considered 
significant.
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